Synthesis and Evaluation of Chiral Rhodanine Derivatives Bearing Quinoxalinyl Imidazole Moiety as ALK5 Inhibitors
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: TGF-β signaling pathway inhibition is considered an effective way to prevent the development of several diseases. In the design and synthesis of TGF-β inhibitors, a rhodanine compound containing a quinoxalinyl imidazole moiety was found to have strong antimicrobial activity.
OBJECTIVE: The purpose of this work was to investigate the antimicrobial activity of other chiral rhodanine TGF-β inhibitors synthesized.
METHODS: Two series of 3-substituted-5-(5-(6-methylpyridin-2-yl)-4-(quinoxalinyl-6-yl)- 1Himidazol- 2-yl)methylene)-2-thioxothiazolin-4-ones (12a-h and 13a-e) were synthesized and evaluated for their ALK5 inhibitory and antimicrobial activity. The structures were confirmed by their 1H NMR, 13C NMR and HRMS spectra. All the synthesized compounds were screened against Grampositive strains, Gram-negative strains, and fungi.
RESULTS: Among the synthesized compounds, compound 12h showed the highest activity (IC50 = 0.416 μM) against ALK5 kinase. Compound 12h exhibited a good selectivity index of >24 against p38α MAP kinase and was 6.0-fold more selective than the clinical candidate, compound 2 (LY- 2157299). Nearly all the compounds displayed high selectivity toward both Gram-positive and Gram-negative bacteria. They also showed similar or 2.0-fold greater antifungal activity (minimum inhibitory concentration [MIC] = 0.5 μg/mL) compared with the positive control compounds Gatifloxacin (MIC = 0.5 μg/mL) and fluconazole (MIC = 1 μg/mL).
CONCLUSION: The findings suggest that the synthesized rhodanine compounds have good ALK5 inhibitory activity, and merit further research and development as potential antifungal drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Medicinal chemistry (Shariqah (United Arab Emirates)) - 18(2022), 4 vom: 04., Seite 509-520 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Li-Min [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7O50LKL2G8 |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1573406417666210628144849 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327299215 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327299215 | ||
| 003 | DE-627 | ||
| 005 | 20231225200454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1573406417666210628144849 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327299215 | ||
| 035 | |a (NLM)34182915 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Li-Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis and Evaluation of Chiral Rhodanine Derivatives Bearing Quinoxalinyl Imidazole Moiety as ALK5 Inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: TGF-β signaling pathway inhibition is considered an effective way to prevent the development of several diseases. In the design and synthesis of TGF-β inhibitors, a rhodanine compound containing a quinoxalinyl imidazole moiety was found to have strong antimicrobial activity | ||
| 520 | |a OBJECTIVE: The purpose of this work was to investigate the antimicrobial activity of other chiral rhodanine TGF-β inhibitors synthesized | ||
| 520 | |a METHODS: Two series of 3-substituted-5-(5-(6-methylpyridin-2-yl)-4-(quinoxalinyl-6-yl)- 1Himidazol- 2-yl)methylene)-2-thioxothiazolin-4-ones (12a-h and 13a-e) were synthesized and evaluated for their ALK5 inhibitory and antimicrobial activity. The structures were confirmed by their 1H NMR, 13C NMR and HRMS spectra. All the synthesized compounds were screened against Grampositive strains, Gram-negative strains, and fungi | ||
| 520 | |a RESULTS: Among the synthesized compounds, compound 12h showed the highest activity (IC50 = 0.416 μM) against ALK5 kinase. Compound 12h exhibited a good selectivity index of >24 against p38α MAP kinase and was 6.0-fold more selective than the clinical candidate, compound 2 (LY- 2157299). Nearly all the compounds displayed high selectivity toward both Gram-positive and Gram-negative bacteria. They also showed similar or 2.0-fold greater antifungal activity (minimum inhibitory concentration [MIC] = 0.5 μg/mL) compared with the positive control compounds Gatifloxacin (MIC = 0.5 μg/mL) and fluconazole (MIC = 1 μg/mL) | ||
| 520 | |a CONCLUSION: The findings suggest that the synthesized rhodanine compounds have good ALK5 inhibitory activity, and merit further research and development as potential antifungal drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Rhodanine | |
| 650 | 4 | |a TGF-beta | |
| 650 | 4 | |a antifungal | |
| 650 | 4 | |a antimicrobial | |
| 650 | 4 | |a docking | |
| 650 | 4 | |a imidazole | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Rhodanine |2 NLM | |
| 650 | 7 | |a 7O50LKL2G8 |2 NLM | |
| 700 | 1 | |a Guo, Fang Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui Min |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Da Qi, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wen Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Piao, Lianxun |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Xuejun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Fen-Er |e verfasserin |4 aut | |
| 700 | 1 | |a Piao, Hu-Ri |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Chang Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Cheng Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry (Shariqah (United Arab Emirates)) |d 2005 |g 18(2022), 4 vom: 04., Seite 509-520 |w (DE-627)NLM163628467 |x 1875-6638 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:4 |g day:04 |g pages:509-520 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1573406417666210628144849 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 4 |b 04 |h 509-520 | ||